LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

TMO

586.32

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

TMO

586.32

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

TMO

586.32

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

TMO

586.32

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

TMO

586.32

+1.79%↑

Search

Design Therapeutics Inc

Suletud

7.66 3.37

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.24

Max

7.76

Põhinäitajad

By Trading Economics

Sissetulek

-1.4M

-19M

Kasumimarginaal

-2,321.599

Töötajad

57

EBITDA

-1.3M

-22M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-25.98% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2025

Turustatistika

By TradingEconomics

Turukapital

148M

373M

Eelmine avamishind

4.29

Eelmine sulgemishind

7.66

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Design Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. nov 2025, 23:59 UTC

Tulu

Singtel's 1st Half Net Profit Surges

11. nov 2025, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11. nov 2025, 22:21 UTC

Tulu

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11. nov 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11. nov 2025, 23:44 UTC

Tulu

Singtel's 1H Net Profit Surges

11. nov 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11. nov 2025, 23:18 UTC

Tulu

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11. nov 2025, 23:15 UTC

Tulu

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11. nov 2025, 23:14 UTC

Tulu

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11. nov 2025, 23:12 UTC

Tulu

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11. nov 2025, 23:11 UTC

Tulu

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11. nov 2025, 23:10 UTC

Tulu

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11. nov 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. nov 2025, 21:50 UTC

Market Talk
Tulu

Health Care Roundup: Market Talk

11. nov 2025, 21:46 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11. nov 2025, 21:41 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11. nov 2025, 21:40 UTC

Tulu

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: Final Dividend 49 Australian Cents/Share

11. nov 2025, 21:37 UTC

Tulu

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11. nov 2025, 21:36 UTC

Tulu

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11. nov 2025, 21:35 UTC

Tulu

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Adj EPS 79c >ALC

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Rev $2.61B >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q EPS 48c >ALC.EB

Võrdlus sarnastega

Hinnamuutus

Design Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-25.98% langus

12 kuu keskmine prognoos

Keskmine 5.5 USD  -25.98%

Kõrge 6 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Design Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

0

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.26 / 3.63Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat